Stryker Corp. (NYSE:SYK) VP Yin C. Becker sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 12th. The shares were sold at an average price of $114.03, for a total value of $1,368,360.00. Following the completion of the sale, the vice president now owns 28,939 shares in the company, valued at $3,299,914.17. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of Stryker Corp. (NYSE:SYK) opened at 114.81 on Wednesday. The company’s 50-day moving average is $115.16 and its 200 day moving average is $114.30. Stryker Corp. has a 12 month low of $86.68 and a 12 month high of $123.55. The company has a market capitalization of $42.97 billion, a price-to-earnings ratio of 27.07 and a beta of 0.72.
Stryker Corp. (NYSE:SYK) last released its quarterly earnings data on Thursday, July 21st. The medical technology company reported $1.39 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.37 by $0.02. Stryker Corp. had a net margin of 15.33% and a return on equity of 23.61%. The company earned $2.84 billion during the quarter, compared to analyst estimates of $2.79 billion. On average, equities research analysts anticipate that Stryker Corp. will post $5.76 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 31st. Investors of record on Friday, September 30th will be paid a $0.38 dividend. This represents a $1.52 dividend on an annualized basis and a yield of 1.32%. The ex-dividend date is Wednesday, September 28th. Stryker Corp.’s dividend payout ratio (DPR) is presently 35.85%.
Several research analysts have recently commented on SYK shares. Zacks Investment Research raised Stryker Corp. from a “hold” rating to a “buy” rating and set a $130.00 target price on the stock in a report on Tuesday, June 21st. Credit Suisse Group AG reissued an “outperform” rating and issued a $124.00 target price (up from $110.00) on shares of Stryker Corp. in a report on Tuesday, July 19th. Piper Jaffray Cos. boosted their target price on Stryker Corp. from $120.00 to $135.00 and gave the stock an “overweight” rating in a report on Friday, July 22nd. JPMorgan Chase & Co. reissued a “hold” rating and issued a $119.00 target price on shares of Stryker Corp. in a report on Friday, July 22nd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Stryker Corp. in a report on Sunday, July 24th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $117.91.
A number of hedge funds have recently added to or reduced their stakes in SYK. Ngam Advisors L.P. raised its stake in Stryker Corp. by 25.6% in the first quarter. Ngam Advisors L.P. now owns 24,311 shares of the medical technology company’s stock valued at $2,608,000 after buying an additional 4,955 shares during the last quarter. NN Investment Partners Holdings N.V. purchased a new stake in Stryker Corp. during the first quarter valued at approximately $1,657,000. Bessemer Group Inc. raised its stake in Stryker Corp. by 0.7% in the first quarter. Bessemer Group Inc. now owns 10,140 shares of the medical technology company’s stock valued at $1,088,000 after buying an additional 73 shares during the last quarter. Aviva PLC raised its stake in Stryker Corp. by 1.4% in the first quarter. Aviva PLC now owns 176,356 shares of the medical technology company’s stock valued at $18,921,000 after buying an additional 2,400 shares during the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. raised its stake in Stryker Corp. by 59.5% in the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,276 shares of the medical technology company’s stock valued at $673,000 after buying an additional 2,340 shares during the last quarter. 75.50% of the stock is owned by institutional investors.
Stryker Corp. Company Profile
Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.
Receive News & Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related companies with MarketBeat.com's FREE daily email newsletter.